Anifrolumab-fnia

CHEBI:CHEBI_752066

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2565286
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
INTRAVENOUS
marketing_start_date
20210730
package_marketing_start_date
20210730
marketing_category
BLA
labeler_name
AstraZeneca Pharmaceuticals LP
manufacturer_name
AstraZeneca Pharmaceuticals LP
active_ingredient_strength
300 mg/2mL
active_ingredient_name
ANIFROLUMAB
generic_name
Anifrolumab-fnia
brand_name
SAPHNELO
brand_name_base
SAPHNELO
product_ndc
0310-3040
application_number
BLA761123
spl_id
bf2407a5-51c6-415c-9a02-29715efdd15f
package_ndc
0310-3040-00
package_description
1 VIAL, GLASS in 1 CARTON (0310-3040-00) / 2 mL in 1 VIAL, GLASS
unii
38RL9AE51Q
spl_set_id
d6203302-2128-41a7-b0b4-0e6c0704d4dc
nui
N0000193968
pharm_class_epc
Type I Interferon Receptor Antagonist [EPC]
pharm_class
Type I Interferon Receptor Antagonists [MoA]
pharm_class_moa
Type I Interferon Receptor Antagonists [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class